Biosimilars & Innovator Biologics

Get the complete picture – the intersection of legal, regulatory and commercial strategies for the innovator and biosimilars marketplace.

September 2020 will mark the 11th time that the “who’s who” of the biosimilars industry will gather for ACI’s Annual Summit on Biosimilars.

The novel coronavirus instigated arguably the most important patent story of the year, as COVID-19 ushered in unforeseen challenges for the biosimilars and innovator biologics industries. While patent approvals stalled during the global pandemic, the pipeline continued to grow.

Even so, the conventional barriers remain, such as lack of familiarity and education that influence the use of biosimilars. Now, more than ever, strategies to overcome these barriers are vital to expand the awareness and understanding of these products in the United States. The need for a solid guiding framework has become more critical than ever before.

This September, join top practitioners and industry thought leaders from the biosimilars and innovator biologics communities as they convene for ACI’s 2020 Summit on Biosimilars & Innovator Biologics, and examine the impact of these critical developments while carving out a path forward.